Institution
Memorial Sloan Kettering Cancer Center
Healthcare•New York, New York, United States•
About: Memorial Sloan Kettering Cancer Center is a healthcare organization based out in New York, New York, United States. It is known for research contribution in the topics: Cancer & Population. The organization has 30293 authors who have published 65381 publications receiving 4462534 citations. The organization is also known as: MSKCC & New York Cancer Hospital.
Topics: Cancer, Population, Breast cancer, Prostate cancer, Radiation therapy
Papers published on a yearly basis
Papers
More filters
••
University of Washington1, University of Helsinki2, University of Oulu3, University of Cambridge4, Ghent University5, City of Hope National Medical Center6, University of Melbourne7, National Health Service8, University of Eastern Finland9, University of Tampere10, University of Utah11, University of Toronto12, Ohio State University13, Case Western Reserve University14, University of Pennsylvania15, University of Florida16, Memorial Sloan Kettering Cancer Center17, Peter MacCallum Cancer Centre18, Mayo Clinic19, McGill University20
TL;DR: The data suggest the breast-cancer risk for PALB2 mutation carriers may overlap with that for BRCA1 mutation carriers, and loss-of-function mutations in PALB1 are an important cause of hereditary breast cancer.
Abstract: The risk of breast cancer for female PALB2 mutation carriers, as compared with the general population, was eight to nine times as high among those younger than 40 years of age, six to eight times as high among those 40 to 60 years of age, and five times as high among those older than 60 years of age. The estimated cumulative risk of breast cancer among female mutation carriers was 14% (95% confidence interval [CI], 9 to 20) by 50 years of age and 35% (95% CI, 26 to 46) by 70 years of age. Breast-cancer risk was also significantly influenced by birth cohort (P < 0.001) and by other familial factors (P = 0.04). The absolute breast-cancer risk for PALB2 female mutation carriers by 70 years of age ranged from 33% (95% CI, 25 to 44) for those with no family history of breast cancer to 58% (95% CI, 50 to 66) for those with two or more first-degree relatives with breast cancer at 50 years of age. CONCLUSIONS Loss-of-function mutations in PALB2 are an important cause of hereditary breast cancer, with respect both to the frequency of cancer-predisposing mutations and to the risk associated with them. Our data suggest the breast-cancer risk for PALB2 mutation carriers may overlap with that for BRCA2 mutation carriers. (Funded by the European Research Council and others.) abstr act
677 citations
••
Memorial Sloan Kettering Cancer Center1, Harvard University2, Boston University3, University of Texas MD Anderson Cancer Center4, American Cancer Society5, Oregon Health & Science University6, University of Utah7, Kaiser Permanente8, University of Minnesota9, University of Colorado Denver10, University of Vermont11, University of Texas Southwestern Medical Center12, Creighton University13, Eastern Virginia Medical School14, Indiana University15
TL;DR: In this article, a careful analytic approach was designed to address all evidence available in the literature to delineate predictors of advanced pathology, both cancer and advanced adenomas, so that patients can be stratified more definitely at their baseline colonoscopy into those at lower risk or increased risk for a subsequent advanced neoplasia.
677 citations
••
TL;DR: Serious late toxicity was unusual despite the delivery of high radiation dose levels in these patients, but the risk of proctitis was significantly reduced with IMRT.
Abstract: Purpose To report the incidence and predictors of treatment-related toxicity at 10 years after three-dimensional conformal radiotherapy (3D-CRT) and intensity-modulated radiotherapy (IMRT) for localized prostate cancer. Methods and Materials Between 1988 and 2000, 1571 patients with stages T1–T3 prostate cancer were treated with 3D-CRT/IMRT with doses ranging from 66 to 81 Gy. The median follow-up was 10 years. Posttreatment toxicities were all graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events. Results The actuarial likelihood at 10 years for the development of Grade ≥2 GI toxicities was 9%. The use of IMRT significantly reduced the risk of gastrointestinal (GI) toxicities compared with patients treated with conventional 3D-CRT (13% to 5%; p p p = 0.01). Among patients who had developed acute symptoms during treatment, the incidence of late toxicity at 10 years was 35%, compared with 12% ( p Conclusions Serious late toxicity was unusual despite the delivery of high radiation dose levels in these patients. Higher doses were associated with increased GI and GU Grade 2 toxicities, but the risk of proctitis was significantly reduced with IMRT. Acute symptoms were a precursor of late toxicities in these patients.
677 citations
••
TL;DR: An updated approach to the diagnosis of idiopathic pulmonary fibrosis is provided, based on a systematic search of the medical literature and the expert opinion of members of the Fleischner Society.
676 citations
••
TL;DR: Using an S-100 extract, it is shown that the addition of recombinant HuR stabilizes VEGF mRNA markedly and support the critical role of HuR in mediating the hypoxic stabilization of V EGF mRNA by hypoxia.
676 citations
Authors
Showing all 30708 results
Name | H-index | Papers | Citations |
---|---|---|---|
Gordon H. Guyatt | 231 | 1620 | 228631 |
Edward Giovannucci | 206 | 1671 | 179875 |
Irving L. Weissman | 201 | 1141 | 172504 |
Craig B. Thompson | 195 | 557 | 173172 |
Joan Massagué | 189 | 408 | 149951 |
Gad Getz | 189 | 520 | 247560 |
Chris Sander | 178 | 713 | 233287 |
Richard B. Lipton | 176 | 2110 | 140776 |
Richard K. Wilson | 173 | 463 | 260000 |
George P. Chrousos | 169 | 1612 | 120752 |
Stephen J. Elledge | 162 | 406 | 112878 |
Murray F. Brennan | 161 | 925 | 97087 |
Lewis L. Lanier | 159 | 554 | 86677 |
David W. Bates | 159 | 1239 | 116698 |
Dan R. Littman | 157 | 426 | 107164 |